Harmony Biosciences Holdings (HRMY)vsJohnson & Johnson (JNJ)
HRMY
Harmony Biosciences Holdings
$41.52
+1.02%
HEALTHCARE · Cap: $2.42B
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 10102% more annual revenue ($97.93B vs $959.90M). JNJ leads profitability with a 21.5% profit margin vs 18.9%. HRMY trades at a lower P/E of 13.5x. HRMY earns a higher WallStSmart Score of 75/100 (B).
HRMY
Strong Buy75
out of 100
Grade: B
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRMY.
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 34.2%
Revenue surging 30.3% year-over-year
Earnings expanding 88.2% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : HRMY
The strongest argument for HRMY centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 18.9% and operating margin at 34.2%. Revenue growth of 30.3% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : HRMY
The primary concerns for HRMY are Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HRMY profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
HRMY carries more volatility with a beta of 0.93 — expect wider price swings.
HRMY is growing revenue faster at 30.3% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
HRMY scores higher overall (75/100 vs 59/100), backed by strong 18.9% margins and 30.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harmony Biosciences Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?